Literature DB >> 25637496

Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.

Bibhu Ranjan Das1, Sangeet Bhaumik, Firoz Ahmad, Aziz Mandsaurwala, Heena Satam.   

Abstract

Somatic mutations of EGFR and KRAS gene represent the most common alterations currently known in NSCLC patients. This study explored the frequency, distribution pattern of EGFR and KRAS mutations in Indian patients. The frequencies of EGFR and KRAS mutations were 29 % (116/400) and 4.5 % (6/132) respectively. Both EGFR and KRAS mutations were prevalent in females, and a trend towards higher mutation frequency was seen in patients under ≥ 60 years age. The presence of EGFR and KRAS mutations were higher in adenocarcinomas in comparison to other histological subtype. Sequencing analysis of EGFR exon 18 revealed Inframe deletion (G709_T710 > A) and missense mutation (K713R). Among exon 19 positive cases, 49.3 % (37/75) were in-frame deletions, of which E746_A750del was frequent. Similarly, ~47 % (35/75) cases showed complex mutation involving indel. Among mutations in exon 20 (N = 9), 8 were substitutions, one showed duplication, while all exon 21 mutations were of the missense types with L858R as the most recurrent type. Sequencing analysis of KRAS exon 1 revealed three different types codon 12 substitutions resulting in c34G > T (G12C) (n = 4), c.35G > A (G12D) (n = 1), and c.35G > T (G12V) (n = 1). In conclusion, the present study is an example of molecular diversity of EGFR and KRAS gene in Indian patients and further confirms that the frequency of EGFR and KRAS mutations varies considerably globally. To the best of our knowledge, this is the first Indian study to evaluate KRAS mutation. The current study also served to identify novel variations that added new insights into the genetic heterogeneity of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25637496     DOI: 10.1007/s12253-014-9874-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  75 in total

1.  Genotyping non-small cell lung cancer (NSCLC) in Latin America.

Authors:  Oscar Arrieta; Andrés Felipe Cardona; Guillermo Federico Bramuglia; Aly Gallo; Alma D Campos-Parra; Silvia Serrano; Marcelo Castro; Alejandro Avilés; Edgar Amorin; Ricardo Kirchuk; Mauricio Cuello; José Borbolla; Omar Riemersma; Henry Becerra; Rafael Rosell
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

2.  Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.

Authors:  Shin Myung Kang; Hyun Ju Kang; Ju Hye Shin; Hoguen Kim; Dong Hwan Shin; Se Kyu Kim; Joo-Hang Kim; Kyung Young Chung; Sung Kyu Kim; Joon Chang
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

3.  Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.

Authors:  Takashi Sone; Kazuo Kasahara; Hideharu Kimura; Kazuto Nishio; Masayuki Mizuguchi; Yasuto Nakatsumi; Kazuhiko Shibata; Yuko Waseda; Masaki Fujimura; Shinji Nakao
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

Review 4.  Lung cancer in India.

Authors:  D Behera; T Balamugesh
Journal:  Indian J Chest Dis Allied Sci       Date:  2004 Oct-Dec

5.  [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].

Authors:  Meng-hong Sun; Fei Yang; Lei Shen; Ling Zhang; Ying Chen; Xu Cai; Xiao-li Zhu; Xiao-yan Zhou
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  2011-10

6.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.

Authors:  Chun-Chieh Wu; Hui-Yu Hsu; Hui-Ping Liu; John Wen-Cheng Chang; Ya-Ting Chen; Wen-Yu Hsieh; Jia-Juan Hsieh; Meng-Shu Hsieh; Yi-Rong Chen; Shiu-Feng Huang
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

8.  Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung.

Authors:  Toshihiro Shiozawa; Genichiro Ishii; Koichi Goto; Kanji Nagai; Sachiyo Mimaki; Shotaro Ono; Seiji Niho; Satoshi Fujii; Yuichiro Ohe; Katsuya Tsuchihara; Atsushi Ochiai
Journal:  Pathol Int       Date:  2013-02-21       Impact factor: 2.534

9.  Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients.

Authors:  A Choughule; V Noronha; A Joshi; S Desai; N Jambhekar; S Utture; A Thavamanni; K Prabhash; A Dutt
Journal:  Indian J Cancer       Date:  2013 Apr-Jun       Impact factor: 1.224

10.  EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.

Authors:  Yoon-La Choi; Jong-Mu Sun; Juhee Cho; Sanjay Rampal; Joungho Han; Bhash Parasuraman; Eliseo Guallar; Genehee Lee; Jeeyun Lee; Young Mog Shim
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more
  7 in total

1.  Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.

Authors:  Sangeet Bhaumik; Firoz Ahmad; Bibhu Ranjan Das
Journal:  Med Oncol       Date:  2016-09-16       Impact factor: 3.064

2.  Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.

Authors:  Timothy F Burns; Hossein Borghaei; Suresh S Ramalingam; Tony S Mok; Solange Peters
Journal:  J Clin Oncol       Date:  2020-10-26       Impact factor: 44.544

3.  Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations.

Authors:  Tengteng Wang; Tao Zhang; Xiaoxue Han; X I Liu; Naikang Zhou; Yang Liu
Journal:  Exp Ther Med       Date:  2015-04-14       Impact factor: 2.447

4.  Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.

Authors:  Varsha Singh; Prerna Guleria; Prabhat Singh Malik; Anant Mohan; Sanjay Thulkar; R M Pandey; Kalpana Luthra; Sudheer Arava; Ruma Ray; Deepali Jain
Journal:  Curr Probl Cancer       Date:  2018-12-17       Impact factor: 3.187

5.  Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro.

Authors:  Rui Lou; Haixia Cao; Shuchen Dong; Chen Shi; Xiaoyue Xu; Rong Ma; Jianzhong Wu; Jifeng Feng
Journal:  Anticancer Drugs       Date:  2019-06       Impact factor: 2.248

Review 6.  Molecular epidemiology and diagnostics of KRAS mutations in human cancer.

Authors:  Jozsef Timar; Karl Kashofer
Journal:  Cancer Metastasis Rev       Date:  2020-12       Impact factor: 9.264

Review 7.  Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner.

Authors:  Christophe Bontoux; Véronique Hofman; Patrick Brest; Marius Ilié; Baharia Mograbi; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.